ADENOSINE INJECTION 3 MG
ADENOSINE : 3 MG · DIN 02457474 · FRESENIUS KABI CANADA LTD
Health Canada status: MARKETED
What is ADENOSINE INJECTION?
ADENOSINE INJECTION 3 MG contains ADENOSINE : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02457474, held by FRESENIUS KABI CANADA LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 17-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ADENOSINE INJECTION used for?
Adenosine Injection is indicated for the conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White syndrome). Adenosine Injection is indicated to aid in the diagnosis of broad or narrow complex supraventricular tachycardia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02457474 |
|---|---|
| Brand name | ADENOSINE INJECTION |
| Generic / active ingredient | ADENOSINE : 3 MG |
| Manufacturer | FRESENIUS KABI CANADA LTD |
| Strength | 3 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | C01EB10 ADENOSINE |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 17-Aug-2017 |
| Original market date | 2017-07-31 00:00:00 |
How is it stored and handled?
controlled room temperature (15 °C to 30 °C). Do not refrigerate as crystallization may occur. If crystallization has occurred, dissolve crystals by warming to room temperature. Retain in carton until time of use.
How is it supplied?
10 x 6 mg/2 mL vials, 10 x 6 mg/2 mL prefilled syringes, 10 x 12 mg/4 mL prefilled syringes
What can be used instead?
Other Canadian products sharing ATC code C01EB10 ADENOSINE. 3 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADENOSINE INJECTION | 3 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02457482 |
| ADENOSINE INJECTION | 3 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02267659 |
| ADENOCARD - LIQ RAPID BOLUS IV 3MG/ML | 3 MG | SOLUTION | ASTELLAS PHARMA CANADA INC | CANCELLED POST MARKET | DIN 02139308 |
| ADENOCARD INJECTION -PRE-FILLED SYRINGE | 3 MG | SOLUTION | ASTELLAS PHARMA CANADA INC | CANCELLED POST MARKET | DIN 02145820 |
| ADENOCARD LIQ IV 3MG/ML | 3 MG | LIQUID | FUJISAWA PHARMACEUTICAL CO, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 02030306 |
| ADENOCARD LIQ IV 3MG/ML (PRE-FILLED SYRINGE) | 3 MG | LIQUID | FUJISAWA PHARMACEUTICAL CO, DIVISION OF FUJISAWA CANADA INC. | CANCELLED POST MARKET | DIN 02031078 |
| ADENOSCAN - (FOR IV INFUSION ONLY) | 3 MG | SOLUTION | ASTELLAS PHARMA CANADA INC | CANCELLED POST MARKET | DIN 02139294 |
| ADENOSINE INJECTION, USP | 3 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | DIN 02401061 |
| ADENOSINE INJECTION, USP | 3 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED PRE MARKET | DIN 02409585 |
| AJ-ADENOSINE | 3 MG | SOLUTION | AGILA JAMP CANADA INC | CANCELLED PRE MARKET | DIN 02402246 |
Who else supplies ADENOSINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ADENOSINE appears in 38 registered pack listings across 7 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.